JP2022526890A5 - - Google Patents
Info
- Publication number
- JP2022526890A5 JP2022526890A5 JP2021556713A JP2021556713A JP2022526890A5 JP 2022526890 A5 JP2022526890 A5 JP 2022526890A5 JP 2021556713 A JP2021556713 A JP 2021556713A JP 2021556713 A JP2021556713 A JP 2021556713A JP 2022526890 A5 JP2022526890 A5 JP 2022526890A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- composition according
- cancer
- formula
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962822486P | 2019-03-22 | 2019-03-22 | |
| US62/822,486 | 2019-03-22 | ||
| US201962934930P | 2019-11-13 | 2019-11-13 | |
| US62/934,930 | 2019-11-13 | ||
| PCT/US2020/023913 WO2020198026A1 (en) | 2019-03-22 | 2020-03-20 | Compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526890A JP2022526890A (ja) | 2022-05-27 |
| JP2022526890A5 true JP2022526890A5 (https=) | 2023-03-28 |
Family
ID=72611715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556713A Pending JP2022526890A (ja) | 2019-03-22 | 2020-03-20 | 化合物及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230078764A1 (https=) |
| EP (1) | EP3941908A4 (https=) |
| JP (1) | JP2022526890A (https=) |
| KR (1) | KR20220003173A (https=) |
| CN (1) | CN114174273A (https=) |
| AU (1) | AU2020245349A1 (https=) |
| BR (1) | BR112021018591A2 (https=) |
| CA (1) | CA3134510A1 (https=) |
| IL (1) | IL286497A (https=) |
| MA (1) | MA55385A (https=) |
| MX (1) | MX2021011488A (https=) |
| SG (1) | SG11202110225SA (https=) |
| WO (1) | WO2020198026A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| EP3566055B1 (en) | 2017-01-06 | 2025-03-12 | Janssen Pharmaceutica NV | Scd inhibitor for the treatment of neurological disorders |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| WO2019183587A1 (en) | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| WO2020154571A1 (en) | 2019-01-24 | 2020-07-30 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| BR112022019517A2 (pt) | 2020-03-30 | 2022-12-06 | Hutchison Medipharma Ltd | Compostos de amida e usos dos mesmos |
| WO2022104011A1 (en) * | 2020-11-12 | 2022-05-19 | Yumanity Therapeutics, Inc. | Methods for the treatment of neurological disorders |
| US20240116962A1 (en) * | 2020-12-31 | 2024-04-11 | Tsinghua University | Pyridine-2-amine derivative and pharmaceutical composition and use thereof |
| EP4337202A4 (en) | 2021-06-18 | 2025-04-02 | Aligos Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 |
| EP4448512A4 (en) | 2021-12-16 | 2025-11-19 | Aligos Therapeutics Inc | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 |
| WO2023111996A1 (en) | 2021-12-17 | 2023-06-22 | Reglagene Holding, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| US12215102B2 (en) | 2023-02-28 | 2025-02-04 | Reglagene, Inc. | Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002092087A1 (en) * | 2001-05-11 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors |
| US7754711B2 (en) * | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| WO2006022442A1 (ja) * | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| MX2007003318A (es) * | 2004-09-20 | 2007-05-18 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
| JP2009537571A (ja) * | 2006-05-22 | 2009-10-29 | メルク フロスト カナダ リミテツド | ステアロイル−コエンザイムａデルタ−９デサチュラーゼのインヒビターとしての環状アミン誘導体 |
| US8080659B2 (en) * | 2006-07-11 | 2011-12-20 | Emory University | CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders |
| WO2008008852A2 (en) * | 2006-07-11 | 2008-01-17 | Emory University | Cxcr4 antagonists including heteroatoms for the treatment of medical disorders |
| EP2271621B1 (en) * | 2008-03-31 | 2013-11-20 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as cftr modulators |
| US20110183958A1 (en) * | 2008-10-17 | 2011-07-28 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| GB201021103D0 (en) * | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
| BR112014007310A2 (pt) * | 2011-09-27 | 2017-04-04 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante |
| DK2776387T3 (en) * | 2011-11-07 | 2017-05-08 | Univ Emory | Tricyclic amino containing compounds to treat or prevent symptoms associated with endocrine dysfunction |
| US8530461B2 (en) * | 2011-12-29 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Azetidine derivatives |
| EP3099682A1 (en) * | 2014-01-29 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| EP3034500A1 (en) * | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
| CN106146391A (zh) * | 2015-04-15 | 2016-11-23 | 中国科学院上海药物研究所 | 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途 |
| SG11201804901WA (en) * | 2015-12-22 | 2018-07-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| CN109689056A (zh) * | 2016-08-01 | 2019-04-26 | 亚尼塔公司 | 用于治疗癌症的组合 |
| EP3566055B1 (en) * | 2017-01-06 | 2025-03-12 | Janssen Pharmaceutica NV | Scd inhibitor for the treatment of neurological disorders |
| EP3381908A1 (en) * | 2017-03-27 | 2018-10-03 | Leadiant Biosciences SA | 2-(4-(4-(bromo-methoxybenzamido)benzylamino)phenyl)benzazole derivatives and their use as anti-heparanase |
| CN110621316B (zh) * | 2017-04-21 | 2024-01-26 | Epizyme股份有限公司 | 用ehmt2抑制剂进行的组合疗法 |
| WO2019183587A1 (en) * | 2018-03-23 | 2019-09-26 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
-
2020
- 2020-03-20 WO PCT/US2020/023913 patent/WO2020198026A1/en not_active Ceased
- 2020-03-20 BR BR112021018591A patent/BR112021018591A2/pt not_active Application Discontinuation
- 2020-03-20 US US17/441,937 patent/US20230078764A1/en not_active Abandoned
- 2020-03-20 SG SG11202110225SA patent/SG11202110225SA/en unknown
- 2020-03-20 AU AU2020245349A patent/AU2020245349A1/en not_active Abandoned
- 2020-03-20 CA CA3134510A patent/CA3134510A1/en active Pending
- 2020-03-20 MX MX2021011488A patent/MX2021011488A/es unknown
- 2020-03-20 JP JP2021556713A patent/JP2022526890A/ja active Pending
- 2020-03-20 EP EP20776951.4A patent/EP3941908A4/en not_active Withdrawn
- 2020-03-20 CN CN202080037767.5A patent/CN114174273A/zh active Pending
- 2020-03-20 MA MA055385A patent/MA55385A/fr unknown
- 2020-03-20 KR KR1020217034310A patent/KR20220003173A/ko not_active Ceased
-
2021
- 2021-09-19 IL IL286497A patent/IL286497A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022526890A5 (https=) | ||
| JP5808408B2 (ja) | フタラジノンケトン誘導体、その製造法および医薬用途 | |
| KR101586112B1 (ko) | 카바졸 화합물 및 이 화합물의 치료학적 용도 | |
| JP2008535903A5 (https=) | ||
| AU2015227454A1 (en) | Functionalised and substituted indoles as anti-cancer agents | |
| IL261852A (en) | Substituted imidazole based compounds for treatment of cancer | |
| CN115087658B (zh) | 具有诱导brd4蛋白质分解作用的磺酰胺或亚磺酰胺化合物及其药物用途 | |
| JP7319977B2 (ja) | チューブリン阻害剤 | |
| JP2007511504A5 (https=) | ||
| BR112017003312B1 (pt) | Compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos | |
| JP2007523862A5 (https=) | ||
| KR20210120070A (ko) | 면역조절제 | |
| RU2016147654A (ru) | Соединения для лечения рака | |
| AU2014273618A1 (en) | Imidazole diketone compound and use thereof | |
| CN104736155A (zh) | 双环化合物作为激酶的抑制剂 | |
| CN118119618A (zh) | 一种杂芳环类化合物及其应用 | |
| RU2003137007A (ru) | Новые пиридилцианогуанидиновые соединения | |
| KR102421137B1 (ko) | 아미노치환 질소함유 축합고리 화합물 및 그의 제조방법과 용도 | |
| WO2021154668A1 (en) | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS | |
| JP4707393B2 (ja) | 抗癌化合物 | |
| CN115210235A (zh) | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 | |
| WO1999040093A2 (en) | Synthesis of quinobenzoxazine analogues with topoisomerase ii and quadruplex interactions for use as antineoplastic agents | |
| EP4097107A1 (en) | C3-substituted 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists | |
| WO2023020604A1 (zh) | 一种五元含氮杂环并杂芳基类衍生物及其用途 | |
| KR20250023311A (ko) | 신규한 화합물, 및 이를 포함하는 암 또는 종양의 예방 또는 치료용 약학적 조성물 |